Liver Diseases  >>  Lipotecan (TLC388)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipotecan (TLC388) / Taiwan Liposome Company
NCT02267213: Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Terminated
2
29
RoW
Lipotecan, Lipotecan, TLC388
Taiwan Liposome Company
Hepatocellular Carcinoma
07/15
07/15

Download Options